Direct-Acting Oral Anticoagulant (DAOC) Score
The DOAC Score estimates bleeding risk in atrial fibrillation patients treated with direct oral anticoagulants 1.
Indications for Use
Used to estimate major bleeding risk in patients with atrial fibrillation receiving a DOAC, aiding decisions on dose selection and intensity of monitoring. Provides individualized bleeding-risk prediction with better discrimination than HAS-BLED in large external validation cohorts (AUC 0.67 vs 0.64; 21,142 patients) 1 [Level II evidence]. Developed/validated from RE‑LY, GARFIELD‑AF, COMBINE‑AF, and RAMQ cohorts with robust internal and external validation 2 [Level II evidence].
Insights & Cautions
Identifies bleeding risk in DOAC‑treated AF but offers only modest discrimination (c‑statistic ~0.73 in derivation) and may overestimate high‑risk categories 1. External validation shows AUC ~0.67 and only slight improvement over HAS‑BLED 2. Use only to flag modifiable risks, not to decide against anticoagulation, as guidelines warn scores should not guide withholding OAC 3.